论文部分内容阅读
ＩＤＥＣ—Ｃ２Ｂ８开始Ⅱ期临床联合试验ＩＤＥＣ药物公司的全Ｂ抗体基因工程产品ＩＤＥＣ－Ｃ２Ｂ８开始Ⅱ期临床试验，该产品与化学药物交替使用治疗轻度Ｂ细胞淋巴瘤，以增加疗效和延长缓解时间，又不明显增加毒性。ＩＤＥＣ－Ｃ２Ｂ８也单独使用治疗淋巴瘤目前正进行...
Phase II Clinical Trial of IDEC-C2B8 IDEC Pharmaceuticals’ All-B Antibody Genetic Engineering Product IDEC-C2B8 Starts Phase II Clinical Trial This product is used interchangeably with chemotherapy to treat mild B-cell lymphoma to increase efficacy and prolong remission , But not significantly increased toxicity. IDEC-C2B8 is also used alone to treat lymphoma currently underway ...